|1.||Socinski, Mark A: 41 articles (05/2015 - 09/2002)|
|2.||Markman, Maurie: 37 articles (03/2014 - 02/2002)|
|3.||Hainsworth, John D: 32 articles (08/2015 - 03/2002)|
|4.||Greco, F Anthony: 24 articles (05/2015 - 03/2002)|
|5.||Johnson, David H: 23 articles (10/2015 - 01/2002)|
|6.||Nakagawa, Kazuhiko: 22 articles (01/2016 - 08/2006)|
|7.||Spigel, David R: 22 articles (05/2015 - 10/2005)|
|8.||Burris, Howard A: 20 articles (12/2015 - 03/2002)|
|9.||Vokes, Everett E: 20 articles (05/2015 - 10/2002)|
|10.||Schiller, Joan H: 19 articles (10/2015 - 01/2002)|
07/01/2008 - "When 2-DG was combined with carboplatin, a marked decrease in tumor burden was observed that was significantly more pronounced than when either agent was given alone. "
01/01/2015 - "This is explained by the Epo-mediated vascular remodeling leading to improved drug delivery as obvious by a more than 2-fold higher carboplatin accumulation and significantly enhanced tumor apoptosis. "
09/03/2013 - "Significantly greater tumor cell apoptosis and less cell proliferation and angiogenesis were measured in tumors of mice treated with continuous carboplatin as compared to both intermittent and control groups. "
03/01/2009 - "Carboplatin dosing based on renal function and therapeutic monitoring have been previously shown to be beneficial in the treatment of children with cancer. "
08/01/1997 - "When carboplatin was added to the treatment schema, significantly greater clonogenic cell killing and tumor regrowth delay were observed as compared to any agent alone or a two-drug combination (CTX/IL-1alpha or CTX/carboplatin). "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/01/2011 - "In this trial, the combination of Genexol® and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. "
11/01/2015 - "Although carboplatin is one of the standard chemotherapeutic agents for non-small cell lung cancer (NSCLC), it has limited therapeutic efficacy due to activation of a survival signaling pathway and the induction of multidrug resistance. "
09/01/1999 - "We conclude that for a moderate carboplatin dose in non-small cell lung cancer, the therapeutic index could be improved if dosage is calculated according to the AUC."
01/01/2012 - "Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. "
03/01/2013 - "Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study."
|3.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2012 - "The results of this study have demonstrated for the first time that the approach of coupling IP administration with FRT liposomal delivery could provide significantly improved therapeutic efficacy of carboplatin in the treatment of metastatic ovarian cancer."
09/01/2013 - "regimen using carboplatin will be beneficial for patients with advanced ovarian cancer. "
11/01/1999 - "Efficacy of 51Cr-EDTA clearance to tailor a carboplatin therapeutic regimen in ovarian cancer patients."
07/01/1997 - "Carboplatin proved to be effective in patients with optimally debulked ovarian cancer. "
09/01/1995 - "CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. "
01/01/2014 - "Taken together, these results suggest that the efficacy of carboplatin in the treatment of high grade ovarian carcinoma can be enhanced by a combinational therapy with MSeA. "
01/01/2014 - "Concurrent weekly carboplatin and radiation therapy yields high response rate with modest disease-free and overall survivals in locally advanced carcinoma of the uterine cervix. "
06/01/2008 - "Continuous IA CBDCA and concurrent radiation therapy can be delivered safely with good efficacy for locally advanced carcinoma of the tongue."
11/15/2000 - "Superselective continuous intraarterial carboplatin and concurrent radiation therapy can be delivered safely with good efficacy for locally advanced carcinomas of the tongue and base of the tongue. "
03/01/2007 - "The current case suggests that combination CBDCA plus weekly PTX is effective against advanced clear cell carcinoma of the endometrium."
|5.||Breast Neoplasms (Breast Cancer)
02/01/2014 - "In results from one part of the I-SPY 2 trial announced at the 2013 San Antonio Breast Cancer Symposium, neoadjuvant veliparib plus carboplatin improved outcomes for women with triple-negative breast cancer. "
01/01/2004 - "Incorporation of carboplatin as a standard agent in first-line treatment of metastatic breast cancer has support from several recent studies. "
04/01/2015 - "Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer."
06/01/2014 - "Adding carboplatin to neoadjuvant wPTX followed by CEF for HER2-negative breast cancer improved the pCR rate and exacerbated hematotoxicity. "
09/01/1983 - "In addition, three patients with refractory metastatic breast cancer responded to CBDCA (two minimal responses and one partial response) with remission durations averaging 3 months. "
|3.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)